BR0010366A - Composto, composição farmacêutica, método de preparar um composto, e, composto para uso em terapia - Google Patents
Composto, composição farmacêutica, método de preparar um composto, e, composto para uso em terapiaInfo
- Publication number
- BR0010366A BR0010366A BR0010366-7A BR0010366A BR0010366A BR 0010366 A BR0010366 A BR 0010366A BR 0010366 A BR0010366 A BR 0010366A BR 0010366 A BR0010366 A BR 0010366A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- carbon atoms
- optionally
- pyrimidinyl
- pyridinyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
"COMPOSTO, COMPOSIçãO FARMACêUTICA, MéTODO DE PREPARAR UM COMPOSTO, E, COMPOSTO PARA USO EM TERAPIA". Um composto de fórmula (I) ou um seu sal farmaceuticamente aceitável, para uso na manufatura de um medicamento para inibição de MEK em um mamífero com uma doença mediada por MEK, em que: n é 0-1; Y é selecionado de -NH-, -O-, -S- ou -NR^ 7^, em que R^ 7^ é alquila de 1-6 átomos de carbono, R^ 6^ é cicloalquila de 3 a 7 átomos de carbono, que pode ser opcionalmente substituída por um ou mais grupos alquila de 1 a 6 átomos de carbono; ou é um anel piridinila, pirimidinila ou fenila; em que o anel piridinila, pirimidinila ou fenila podem ser substituídos por um, dois ou três substituintes especificados; ou R^ 6^ é um grupo -R^ 8^-X-R^ 9^, em que R^ 8^ é uma cicloalquila divalente de 3 a 7 átomos de carbono, que pode ser opcionalmente substituída ainda por um ou mais grupos alquila de 1 a 6 átomos de carbono; ou é opcionalmente um anel piridinila, pirimidinila ou fenila; em que o anel piridinila, pirimidinila ou fenila pode ser opcionalmente substituído ainda por um ou mais substituintes especificados, X é selecionado de CH~ 2~, -NH-, -O-, -S- ou -NR^ 5^, em que R^ 5^ é alquila de 1-6 átomos de carbono e R^ 9^ é um grupo (CH~ 2~)~ m~R^ 10^ em que m é 0, ou um número inteiro de 1-3 e R^ 10^ é um anel arila opcionalmente substituída ou cicloalquila opcionalmente substituída de até 10 átomos de carbono, ou R^ 10^ é um anel heterocíclico contendo 1 ou 2 átomos de oxigênio e, opcionalmente, um ou mais substituintes; e R^ 1^, R^ 2^, R^ 3^ e R^ 4^ são, cada um independentemente, selecionados de hidrogênio ou vários grupos orgânicos especificados. Os novos compostos são também descritos e reivindicados.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9910580.1A GB9910580D0 (en) | 1999-05-08 | 1999-05-08 | Chemical compounds |
PCT/GB2000/001698 WO2000068199A1 (en) | 1999-05-08 | 2000-05-03 | Quinoline derivatives as inhibitors of mek enzymes |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0010366A true BR0010366A (pt) | 2002-02-13 |
Family
ID=10852989
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0010366-7A BR0010366A (pt) | 1999-05-08 | 2000-05-03 | Composto, composição farmacêutica, método de preparar um composto, e, composto para uso em terapia |
Country Status (16)
Country | Link |
---|---|
US (1) | US6638945B1 (pt) |
EP (1) | EP1178965B1 (pt) |
JP (1) | JP2002544194A (pt) |
KR (1) | KR20020000803A (pt) |
CN (1) | CN1350524A (pt) |
AT (1) | ATE250582T1 (pt) |
AU (1) | AU4589200A (pt) |
BR (1) | BR0010366A (pt) |
CA (1) | CA2371469A1 (pt) |
DE (1) | DE60005504T2 (pt) |
GB (1) | GB9910580D0 (pt) |
IL (1) | IL146319A0 (pt) |
NO (1) | NO20015447L (pt) |
TR (1) | TR200103185T2 (pt) |
WO (1) | WO2000068199A1 (pt) |
ZA (1) | ZA200108969B (pt) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1365796A2 (en) | 2000-09-01 | 2003-12-03 | Van Andel Institute | Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma |
US7067532B2 (en) * | 2000-11-02 | 2006-06-27 | Astrazeneca | Substituted quinolines as antitumor agents |
US7253184B2 (en) | 2000-11-02 | 2007-08-07 | Astrazeneca Ab | 4-Substituted quinolines as antitumor agents |
US6603005B2 (en) | 2000-11-15 | 2003-08-05 | Aventis Pharma S.A. | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them |
US6602884B2 (en) | 2001-03-13 | 2003-08-05 | Aventis Pharma S.A. | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them |
EP1377312A4 (en) * | 2001-03-22 | 2004-10-06 | Andel Inst Van | ANTHRAX LETAL FACTOR INHIBITS TUMOR GROWTH AND ANGIOGENESIS |
GB0112834D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
GB0215823D0 (en) * | 2002-07-09 | 2002-08-14 | Astrazeneca Ab | Quinazoline derivatives |
GB0225579D0 (en) | 2002-11-02 | 2002-12-11 | Astrazeneca Ab | Chemical compounds |
EP1633718B1 (en) * | 2003-06-17 | 2012-06-06 | Millennium Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR INHIBITING TGF-s |
EP2210607B1 (en) * | 2003-09-26 | 2011-08-17 | Exelixis Inc. | N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer |
JPWO2007132867A1 (ja) | 2006-05-15 | 2009-09-24 | 杉本 芳一 | 癌の予防及び治療剤 |
KR20120011093A (ko) * | 2007-05-09 | 2012-02-06 | 화이자 인코포레이티드 | 치환된 헤테로사이클릭 유도체 및 조성물 및 항균제로서의 이의 약학적 용도 |
KR20200137052A (ko) | 2009-01-16 | 2020-12-08 | 엑셀리시스, 인코포레이티드 | 암의 치료를 위한 n-(4-{〔6,7-비스(메틸옥시)퀴놀린-4-일〕옥시}페닐)-n'-(4-플루오로페닐)사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형 |
EA201270051A1 (ru) * | 2009-06-25 | 2012-05-30 | Амген Инк. | Гетероциклические соединения и их применения |
UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
WO2012018638A2 (en) | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
US9845489B2 (en) | 2010-07-26 | 2017-12-19 | Biomatrica, Inc. | Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
WO2014100755A2 (en) | 2012-12-20 | 2014-06-26 | Biomatrica, Inc. | Formulations and methods for stabilizing pcr reagents |
WO2014127214A1 (en) | 2013-02-15 | 2014-08-21 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
ES2831625T3 (es) | 2013-02-20 | 2021-06-09 | Kala Pharmaceuticals Inc | Compuestos terapéuticos y sus usos |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
CA2915250A1 (en) | 2013-06-13 | 2015-01-08 | Biomatrica, Inc. | Cell stabilization |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
JP6426194B2 (ja) | 2013-11-01 | 2018-11-21 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物の結晶形態及びその使用 |
ES2786373T3 (es) | 2014-06-10 | 2020-10-09 | Biomatrica Inc | Estabilización de trombocitos a temperaturas ambiente |
US20190008859A1 (en) | 2015-08-21 | 2019-01-10 | Acerta Pharma B.V. | Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor |
EP3359526A4 (en) | 2015-10-05 | 2019-04-03 | The Trustees of Columbia University in the City of New York | ACTIVATORS OF AUTOPHAGIC FLOW AND PHOSPHOLIPASE D AND CLAIRANCE OF PROTEIN AGGREGATES COMPRISING TAU AND TREATMENT OF PROTEINEOPATHIES |
ES2946184T3 (es) | 2015-12-08 | 2023-07-13 | Biomatrica Inc | Reducción de la velocidad de eritrosedimentación |
CN106220560A (zh) * | 2016-07-27 | 2016-12-14 | 华侨大学 | 一种多取代喹啉衍生物的制备方法 |
US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
EP3509421A4 (en) | 2016-09-08 | 2020-05-20 | Kala Pharmaceuticals, Inc. | CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF |
US10392399B2 (en) | 2016-09-08 | 2019-08-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
KR20230081932A (ko) | 2021-11-30 | 2023-06-08 | 주식회사 메타뷰 | 실내 위치 측위 정보를 모니터링하는 고온환경 스마트 팩토리 안전관리 시스템 및 그 방법 |
KR102557537B1 (ko) | 2022-08-25 | 2023-07-20 | 김형미 | 개선된 통신 방식을 활용한 스마트 도어 제어 방법, 장치 및 시스템 |
KR102498884B1 (ko) | 2022-11-04 | 2023-02-10 | 주식회사 레딕스 | 현장 작업자와 화물차 기사의 안전관리를 위한 안전관리 시스템 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE317376B (pt) | 1961-07-10 | 1969-11-17 | Roussel Uclaf | |
FR2077455A1 (en) | 1969-09-03 | 1971-10-29 | Aries Robert | 5-haloveratryl-4-aminoquinoles - antimalarials amoebicides anthelmintics anticoccidials |
US3936461A (en) | 1973-09-24 | 1976-02-03 | Warner-Lambert Company | Substituted 4-benzylquinolines |
FR2498187A1 (fr) | 1981-01-16 | 1982-07-23 | Rhone Poulenc Sante | Procede de preparation d'amino-4 chloro-7 quinoleines |
IL81307A0 (en) | 1986-01-23 | 1987-08-31 | Union Carbide Agricult | Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives |
IL89029A (en) | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
SG64322A1 (en) | 1991-05-10 | 1999-04-27 | Rhone Poulenc Rorer Int | Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5506235A (en) | 1991-08-02 | 1996-04-09 | Pfizer Inc. | Quinoline derivatives as immunostimulants |
US5656643A (en) | 1993-11-08 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
US5650415A (en) | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
WO1997017329A1 (fr) | 1995-11-07 | 1997-05-15 | Kirin Beer Kabushiki Kaisha | Derives de quinoline et derives de quinazoline inhibant l'autophosphorylation d'un recepteur de facteur de croissance originaire de plaquettes, et compositions pharmaceutiques les contenant |
ES2186908T3 (es) | 1996-07-13 | 2003-05-16 | Glaxo Group Ltd | Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas. |
NZ334125A (en) * | 1996-09-25 | 2000-10-27 | Zeneca Ltd | Quinoline derivatives inhibiting the effect of growth factors such as VEGF |
UA73073C2 (uk) * | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
WO1999001426A1 (en) | 1997-07-01 | 1999-01-14 | Warner-Lambert Company | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
ES2274572T3 (es) * | 1997-07-01 | 2007-05-16 | Warner-Lambert Company Llc | Derivados de acido 2-(4-bromo- o 4-yodo-fenilamino) benzoico y su uso como inhibidor de mek. |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
CN1144786C (zh) | 1998-09-29 | 2004-04-07 | 美国氰胺公司 | 作为蛋白质酪氨酸激酶抑制剂的取代的3-氰基喹啉 |
BR9914167B1 (pt) | 1998-09-29 | 2011-03-09 | compostos e composições farmacêuticas compreendendo 3-ciano quinolinas substituìdas. |
-
1999
- 1999-05-08 GB GBGB9910580.1A patent/GB9910580D0/en not_active Ceased
-
2000
- 2000-05-03 TR TR2001/03185T patent/TR200103185T2/xx unknown
- 2000-05-03 WO PCT/GB2000/001698 patent/WO2000068199A1/en not_active Application Discontinuation
- 2000-05-03 US US09/959,434 patent/US6638945B1/en not_active Expired - Fee Related
- 2000-05-03 AT AT00927492T patent/ATE250582T1/de not_active IP Right Cessation
- 2000-05-03 BR BR0010366-7A patent/BR0010366A/pt not_active IP Right Cessation
- 2000-05-03 KR KR1020017014194A patent/KR20020000803A/ko not_active Application Discontinuation
- 2000-05-03 IL IL14631900A patent/IL146319A0/xx unknown
- 2000-05-03 AU AU45892/00A patent/AU4589200A/en not_active Abandoned
- 2000-05-03 CN CN00807302A patent/CN1350524A/zh active Pending
- 2000-05-03 EP EP00927492A patent/EP1178965B1/en not_active Expired - Lifetime
- 2000-05-03 JP JP2000617179A patent/JP2002544194A/ja active Pending
- 2000-05-03 DE DE60005504T patent/DE60005504T2/de not_active Expired - Fee Related
- 2000-05-03 CA CA002371469A patent/CA2371469A1/en not_active Abandoned
-
2001
- 2001-10-30 ZA ZA200108969A patent/ZA200108969B/en unknown
- 2001-11-07 NO NO20015447A patent/NO20015447L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ZA200108969B (en) | 2003-01-30 |
TR200103185T2 (tr) | 2002-05-21 |
CA2371469A1 (en) | 2000-11-16 |
AU4589200A (en) | 2000-11-21 |
DE60005504D1 (de) | 2003-10-30 |
NO20015447D0 (no) | 2001-11-07 |
DE60005504T2 (de) | 2004-06-24 |
EP1178965A1 (en) | 2002-02-13 |
US6638945B1 (en) | 2003-10-28 |
KR20020000803A (ko) | 2002-01-05 |
NO20015447L (no) | 2001-12-12 |
JP2002544194A (ja) | 2002-12-24 |
ATE250582T1 (de) | 2003-10-15 |
CN1350524A (zh) | 2002-05-22 |
WO2000068199A1 (en) | 2000-11-16 |
GB9910580D0 (en) | 1999-07-07 |
EP1178965B1 (en) | 2003-09-24 |
IL146319A0 (en) | 2002-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0010366A (pt) | Composto, composição farmacêutica, método de preparar um composto, e, composto para uso em terapia | |
BR0010324A (pt) | Composto, composição farmacêutica, e, método de preparação de um composto | |
EA200000731A1 (ru) | Альфа-аминоамидные производные, полезные в качестве анальгетических агентов | |
IS6138A (is) | Kínólín afleiður sem latar fyrir MEK ensím | |
NO914960D0 (no) | Medikamenter for canserterapi med antihistaminegenskaper | |
NO163855C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive arylcyklobutylalkylaminer. | |
AU581324B2 (en) | Substituted 6-phenyl-4,5-dihydro pyradazin-3-ones | |
ATE34753T1 (de) | Derivate von pristinamycin iib, deren herstellung und deren pharmazeutische zusammensetzungen. | |
NO890440D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive isokinolinderivater. | |
IE56000B1 (en) | 1-arylcyclobutylalkylamine compounds | |
PT89082A (pt) | Processo para a preparacao de novos derivados n-(23-vinblastinoilicos)do acido 1-amino-metilfosfonico | |
ES2084120T3 (es) | Medicamentos para prevenir y tratar enfermedades del aparato circulatorio que contienen compuestos de espiro-3-heteroazolidina. | |
SE8800863L (sv) | 3-(2-haloalkyl)-1,4-oxatiiner och 2-(2-haloalkyl)1,4-ditiiner och bahandling av leukemi och tumoerer daermed | |
ATE18761T1 (de) | Carbamoyloxybenzhydrol-derivate, ihre herstellung und ihre pharmazeutische zusammensetzungen. | |
DE69409734T2 (de) | Neue Derivate des 2-(1H)-Chinolinones, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel | |
DE3167968D1 (en) | Cyclopropyl methyl piperazines, process for their preparation and their use in therapeutics | |
MX9204212A (es) | Preparado de combinacion farmaceutico. | |
DE69301639T2 (de) | Tetrahydronaphtalenderivate, ihre Herstellung und ihre therapeutische Verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1927 DE 11/12/2007. |